Latest / Durham News Today | 2 Min News | The Daily News Now!
J&J’s Bold Restructuring Revealed | Durham News
Johnson & Johnson is executing a bold corporate reset—spinning off its world-leading orthopaedics division to focus laser-sharp on high-growth oncology, immunology, and neuroscience. With record $100B in revenue and a 64-year dividend streak, the company’s strategic pivot is already paying off: oncology sales are projected to hit $50B by 2030, fueled by blockbuster cancer drugs. A major legal hurdle around talc lawsuits is also being resolved, removing investor uncertainty. All eyes turn December 8th for their Enterprise Business Review, where J&J will unveil its long-term growth…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.